After a seven-year legal battle, Pfizer Inc. has agreed to settle a government complaint alleging its Wyeth subsidiary offered steep discounts to hospitals that purchased both its oral and IV Protonix (pantoprazole) acid-suppressant drugs while reporting higher prices to the government. The settlement could lead firms to be more careful in how they link pricing of their products in contracts.
Pfizer Protonix Settlement May Deter Price Bundling
$784.6m fine will resolve claims that Wyeth subsidiary paid hospitals steep discounts if they purchased both oral and IV Protonix while reporting higher prices to the government.